Process Validation in Biologics Development
Process validation is an extension of biologics development processes.
When it comes to outsourcing process validation of biologics, Abel Hastings, director of process sciences at FUJIFILM Diosynth Biotechnologies, says that the relationship between a contract development and manufacturing organization (CDMO) and sponsor is key in ensuring successful process validation. “Customers that are open about their strategy, their data (good and bad), and their own strengths and weaknesses are most successful.”
BioPharm International spoke with Hastings about the specific challenges that arise in the process validation of biologics.
Read this article in BioPharm International's Outsourcing Resources 2018 eBook.
View other articles in BioPharm International'sOutsourcing Resources 2018 eBook.
Article Details
BioPharm Internationalâ¨
eBook: Outsourcing Resources 2018
â¨Vol. 31â¨
March 2018â¨
Pages: 22–23
Citation
When referring to this article, please cite it as S. Haigney, "Process Validation in Biologics Development," BioPharm International Outsourcing Resources eBook (March 2018).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
